HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Axel Noetzold Hans-Hinrich Sievers Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Depping, R. Articles by Wagner, K. F. Search for Related Content PubMed PubMed Citation Articles by Depping, R. Articles by Wagner, K. F. Related Collections Cardiac - physiology Myocardial protection

J Thorac Cardiovasc Surg 2005;130:877
© 2005 The American Association for Thoracic Surgery

Brief Communication

Expression of the erythropoietin receptor in human heart

^a Department of Physiology, University Luebeck, Luebeck, Germany
^b Clinic of Cardiac Surgery, University Luebeck, Luebeck, Germany
^c Clinic of Anesthesiology, University Luebeck, Luebeck, Germany
^d Kidney Center Duisburg, Duisburg, Germany

Received for publication December 20, 2004; accepted for publication December 27, 2004.

^_* Address for reprints: Klaus F. Wagner, MD, Department of Anesthesiology, University Luebeck, Ratzeburger Allee 160, D-23538 Luebeck, Germany (Email: wagner@physio.uni-luebeck.de).

The first 20% of the full text of this article appears below.

Dr Wagner

Erythropoietin (EPO), the kidney hormone regulating erythrocyte production, activates the erythropoietin receptor (EPOR), resulting in antiapoptosis. To investigate the clinical significance of EPOR expressed in neuronal cells of the brain, EPO was administered to patients within 8 hours of the onset of stroke symptoms, which ultimately resulted in the reduction of cerebral infarct size and improvement of functional neurologic performance. ¹

Rodents treated with EPO in an animal model of myocardial ischemia and infarction recently demonstrated superior myocardial function. ^2,3 The expression of the EPOR was shown for a variety of rodent and rabbit primary and permanent cardiomyocyte cell lines. But, as noted by several investigators, ^2,3 proof of the presence of the EPOR in the adult human heart is missing.

To overcome this deficit, we investigated adult human ventricular and atrial tissue for the expression of the EPOR.

Methods

The study was approved by the institutional review board, and written informed consent was obtained from all participants. In patients with severe aortic valvular stenosis (valve area < 0.7 cm²), ventricular tissue was obtained from the muscular septum obstructing the left ventricular outflow tract (Morrow procedure) and snap-frozen for RNA and protein analysis or formalin-fixed for immunohistologic analysis (n = 4 per group). Right atrial tissue from the site of the venous cannulation was processed accordingly. Samples were analyzed with reverse transcriptase-polymerase chain reaction, Western blot, and standard or double immunohistochemistry as described in the online supplement.

Results and Discussion

In this report we provide evidence of the expression of the EPOR in adult human ventricular and atrial tissue. Western blots (Figure 1) and reverse transcriptase-polymerase chain reaction (Figure E1) from human ventricular and atrial tissue homogenates indicate the . . . [Full Text of this Article]

This article has been cited by other articles:

				A. J. Ludman, D. M. Yellon, J. Hasleton, C. Ariti, G. G. Babu, E. Boston-Griffiths, V. Venugopal, M. Walker, D. Holdright, H. Swanton, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial Heart, October 1, 2011; 97(19): 1560 - 1565. [Abstract] [Full Text] [PDF]

				A. S. Lee, D. H. Kim, J. E. Lee, Y. J. Jung, K. P. Kang, S. Lee, S. K. Park, J. Y. Kwak, S. Y. Lee, S. T. Lim, et al. Erythropoietin Induces Lymph Node Lymphangiogenesis and Lymph Node Tumor Metastasis Cancer Res., July 1, 2011; 71(13): 4506 - 4517. [Abstract] [Full Text] [PDF]

				D. Choi, S. A. Schroer, S. Y. Lu, L. Wang, X. Wu, Y. Liu, Y. Zhang, H. Y. Gaisano, K.-U. Wagner, H. Wu, et al. Erythropoietin protects against diabetes through direct effects on pancreatic {beta} cells J. Exp. Med., December 20, 2010; 207(13): 2831 - 2842. [Abstract] [Full Text] [PDF]

				P. van der Meer, E. Lipsic, and D. J. van Veldhuisen Asialoerythropoietin to Protect the Failing Heart: Is it Possible to Run With the Hare and Hunt With the Hounds? J. Am. Coll. Cardiol., November 30, 2010; 56(23): 1959 - 1960. [Full Text] [PDF]

				K. Smith, D. Semple, S. Bhandari, and A.-M. L. Seymour Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail, August 1, 2009; 11(8): 732 - 738. [Abstract] [Full Text] [PDF]

				S. Chanseaume, K. Azarnoush, A. Maurel, V. Bellamy, S. Peyrard, P. Bruneval, A. A. Hagege, and P. Menasche Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium? Interact CardioVasc Thorac Surg, June 1, 2007; 6(3): 293 - 297. [Abstract] [Full Text] [PDF]